Leaps by Bayer has put $50m into xenotransplantation technology developer eGenesis as part of a $100m series B round that followed a $38m series A backed by Heritage Provider Network.

US-based gene editing technology developer eGenesis yesterday closed a $100m series B round that featured Leaps by Bayer, an investment vehicle for pharmaceuticals and chemicals producer Bayer. Fresenius Medical Care Ventures led the round, which also included Wellington Partners, Arch Venture Partners, Biomatics Capital, Alta Partners, Khosla Ventures and unnamed, existing investors. Leaps by Bayer…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.